Advocacy and Education Collaborations

Global Liver Alliance - Liver Action Network

This initiative connects liver patients, caregivers, and providers with policymakers on urgent policy changes to improve the liver patient experience.

Canadian Institutes of Health Research (CIHR)

The Canadian Institutes of Health Research (CIHR) is Canada's federal funding agency for health research. Composed of 13 Institutes, we collaborate with partners and researchers to support the discoveries and innovations that improve our health and strengthen our health care system.

Canadian Obesity Advocacy Network (COAN)

The Canadian Obesity Advocacy Network (COAN) is a diverse network of forward-thinking NGOs, companies, foundations, agencies, academics, clinicians and groups of people living with obesity that have come together with the purpose of changing the narrative of obesity in Canada. The COAN sits under the umbrella of Obesity Canada and is committed to collectively addressing bias and stigma, education, access to care and advocacy in Canada.

ELPA

ELPA’s aim is to promote the interests of people with liver disease and in particular: to highlight the size of the problem; to promote awareness and prevention; to address the low profile of liver disease as compared to other areas of medicine such as heart disease; to share experience of successful initiatives; to work with professional bodies such as EASL and with the EU to ensure that treatment and care are harmonised across Europe to the highest standards.

awareNASH

AwareNASH is a research project with the objective to educate clinicians managing patients with NAFLD and NASH on the importance of prompt diagnosis (especially in the case of NASH), along with the relationship of NAFLD/NASH to metabolic disease and CVD. It is funded by an independent educational grant provided by Pfizer.

6th Annual NASH Summit Dec2022

The 6th Annual NASH Summit is your best opportunity to unite with fellow NASH drug developers to gain critical updates on the trailblazing research you need to meaningfully reassess your therapeutic approach and optimize your pipeline strategy for the future.

Metabolism and Target Organ Damage

Metabolism and Target Organ Damage (M&TOD, https://mtodjournal.net ) is an international, peer-reviewed, open-access interdisciplinary journal that provides an online platform for the publication of clinical, basic, and translational studies. It covers (cardio)-metabolic disorders per se, such as obesity, diabetes, dyslipidemias, arterial hypertension, and hyperuricemia in all age groups. Of note, this journal will emphasize the role of these metabolic disorders as either effectors/amplifiers or consequences of the development and progression of injuries to target organs including but not limited to the cardiovascular system, the liver, kidneys, and the pancreas. Specific applications in metabolic disorders are as follows: history of the disease, epidemiology, prevention, natural history, genetics, cell, and molecular biology, pathobiochemistry, physiopathology, anatomic pathology, clinical chemistry, pharmaceutical chemistry, pharmacology, psychology, psychiatry, statistics, and immunology.

Our NAFLD Studies: https://mtodjournal.net/search/search?clearPageContext=1&searchJournal=26&searchVal=fatty+liver

Visit site

badgut.org

We’re committed to improving the lives of people with gastrointestinal and liver conditions, supporting research, advocating for appropriate patient access to healthcare, and promoting gastrointestinal and liver health.